Update of insulin-like growth factor-Ⅰ receptor and its role in Graves′ orbitopathy / 中华内分泌代谢杂志

ABSTRACT

Graves′ orbitopathy is one of the complications related to Graves′ disease. Currently, there is still no available medical therapy provides reliable and safe benefit. Basic and clinical researches on insulin-like growth factor-Ⅰ(IGF-Ⅰ)receptor have found that IGF-Ⅰ receptor has implicated in the pathogenesis of Graves′ orbitopathy. As an IGF-Ⅰ receptor monoclonal antibody, teprotumumab was recently approved for this indication in the United States. It suggested that the therapy targeting on IGF-Ⅰ receptor pathway will soon take its place in the therapeutic armamentarium for active Graves′ orbitopathy.